The information on this site is intended for US healthcare professionals and clinical staff only.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) RECOMMEND idelalisib (ZYDELIG®) monotherapy as an option for appropriate patients with relapsed/refractory lymphoma.1*View efficacy
*Please see the complete version of the NCCN Guidelines® for B-cell Lymphomas (V.4.2020) available on NCCN.org for specific recommendations.
Updated results from finalanalysis of the pivotal trial View efficacy
ZYDELIG is a PI3Kδ inhibitor indicated for
FL and SLL are approved based on overall response rate. Improvement in patient survival or disease-related symptoms has not been established. Continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials.
ZYDELIG is not indicated or recommended for first-line treatment of any patient or in combination with bendamustine and/or rituximab for the treatment of FL.